Study assessments
DLTs, Cancer
ADVERSE EVENT, DISEASE, CANCER
Primary objectives to assess the safety and tolerability of rivoceranib in combination with pembrolizumab were based on the rate of AEs, SAEs, and DLTs. All AEs and SAEs were graded with the National Cancer Institute Common Terminology Criteria for Adverse Events (v5.0).Peripheral blood samples for correlative studies were collected before the beginning of the study drug treatment, after the completion of 2 cycles (21-day cycles), and at the time of progression or treatment discontinuation.Disease assessments were performed every 9 weeks (± 1 week) with computed tomography scans of the chest, abdomen, and pelvis and treatment response was determined utilizing RECIST 1.1.